The increasing prevalence of allergic diseases are becoming a major global health concern. These allergic diseases may appear disparate based on their distinct organ and tissue manifestations and are treated as such within our health care systems, respectively by dermatologists, pulmonologists and ENT physicians. A better understanding of type 2 inflammation and treatment modalities is necessary.
However, this fragmentation does not serve the new way of addressing type 2 inflammatory diseases. Focusing on the underlying pathway driving these diseases leads to a better understanding of type 2 inflammation and treatment modalities, giving rise to a new era of personalized therapy.
Dr. Edward Knol, biomedical scientist and immunologist, UMC Utrecht, talks with several experts about this complex subject. You can watch the video's on this page. Create an account or log in with your existing account on this website.
- Focus on diagnostics and the importance of biomarkers in patients with asthma disease (Dr. Gert-Jan Braunstahl, pulmonologist, Franciscus Gasthuis & Vlietland)
- Signs and Symptoms of AD Impact Multiple Aspects of Quality of Life (Prof. dr. Jan Gutermuth, dermatologist, UZ Brussel)
- Operate or medicate? (Prof. dr. Claus Bachert, ENT-specialist, Ghent University)